Company reports Q2 2026 revenue of $21.7 million, up 18% year-over-year, targeting profitability by late 2026.
AVITA Medical projected 2026 revenue between $86 million and $89 million, aiming for cash flow break-even in Q4 2026. The guidance follows a strong Q2 2026 performance, with revenue reaching $21.7 million, an 18% increase year-over-year and 13% sequentially.
The growth was driven by expanded use of its acute wound care portfolio, according to management. Prior quarter revenue stood at $19.2 million, with consensus estimates hovering near $21 million for Q2 2026.
No immediate market reaction was disclosed in the earnings call summary.